Guselkumab Demonstrates Favorable Benefit-Risk Profile in Biologic-Naive Patients With Active Psoriatic Arthritis
In both the DISCOVER-1 and DISCOVER-2 trials, the researchers assessed guselkumab treatment in biologic-naive patients with active psoriatic arthritis.